Home | Molecular Cancer Therapeutics

April 2020
Read the April 2020 issue, including two First Disclosure articles!
First Disclosure: Preclinical Activity of HER2-Selective Tyrosine Kinase Inhibitor Tucatinib as a Single Agent or in Combination with Trastuzumab or Docetaxel in Solid Tumor Models
Anita Kulukian, et al.
First Disclosure: Characterization of 7A5: A Human CD137 (4-1BB) Receptor Binding Monoclonal Antibody with Differential Agonist Properties That Promotes Antitumor Immunity
Helen Kotanides, et al.
Molecular Cancer Therapeutics: A Central Hub for First Disclosures in Cancer
Read the editorial by our editor-in-chief, Beverly A. Teicher, outlining her vision for MCT as a central source for first disclosures.

From the Current Issue

Review

A Historic Perspective and Overview of H-Ras Structure, Oncogenicity, and Targeting

Lihua Shu, Dongsheng Wang, Nabil F. Saba and Zhuo G. Chen

Mol Cancer Ther April 1 2020 19 (4) 999-1007; DOI:10.1158/1535-7163.MCT-19-0660
Small Molecule Therapeutics

Aurora B Kinase Promotes CHIP-Dependent Degradation of HIF1α in Prostate Cancer Cells

Kuntal Biswas, Sukumar Sarkar, Neveen Said, David L. Brautigan and James M. Larner

Mol Cancer Ther April 1 2020 19 (4) 1008-1017; DOI:10.1158/1535-7163.MCT-19-0777
Large Molecule Therapeutics

Epitope and Fc-Mediated Cross-linking, but Not High Affinity, Are Critical for Antitumor Activity of CD137 Agonist Antibody with Reduced Liver Toxicity

Sun K. Ho, Zhenghai Xu, Archana Thakur, Melvin Fox, Siu Sze Tan, Enrico DiGiammarino, Li Zhou, Mien Sho, Belinda Cairns, Vivian Zhao, Mengli Xiong, Josue Samayoa, Charles M. Forsyth, David B. Powers, Debra T. Chao, Diane Hollenbaugh, Hamsell M. Alvarez and Yoshiko Akamatsu

Mol Cancer Ther April 1 2020 19 (4) 1040-1051; DOI:10.1158/1535-7163.MCT-19-0608
Companion Diagnostic, Pharmacogenomic, and Cancer Biomarkers

Oxaliplatin–DNA Adducts as Predictive Biomarkers of FOLFOX Response in Colorectal Cancer: A Potential Treatment Optimization Strategy

Maike Zimmermann, Tao Li, Thomas J. Semrad, Chun-Yi Wu, Aiming Yu, George Cimino, Michael Malfatti, Kurt Haack, Kenneth W. Turteltaub, Chong-xian Pan, May Cho, Edward J. Kim and Paul T. Henderson

Mol Cancer Ther April 1 2020 19 (4) 1070-1079; DOI:10.1158/1535-7163.MCT-19-0133
Models and Technologies

High-Throughput Generation of Bispecific Binding Proteins by Sortase A–Mediated Coupling for Direct Functional Screening in Cell Culture

Fabio Andres, Martin Schwill, Ykelien L. Boersma and Andreas Plückthun

Mol Cancer Ther April 1 2020 19 (4) 1080-1088; DOI:10.1158/1535-7163.MCT-19-0633

See the Table of Contents

Recent Reviews

Review

The Ongoing Search for Biomarkers of CDK4/6 Inhibitor Responsiveness in Breast Cancer

Scott F. Schoninger and Stacy W. Blain

Mol Cancer Ther January 1 2020 19 (1) 3-12; DOI:10.1158/1535-7163.MCT-19-0253
Review | AuthorChoice

Cabozantinib in Combination with Immunotherapy for Advanced Renal Cell Carcinoma and Urothelial Carcinoma: Rationale and Clinical Evidence

Paulo Bergerot, Peter Lamb, Evelyn Wang and Sumanta K. Pal

Mol Cancer Ther December 1 2019 18 (12) 2185-2193; DOI:10.1158/1535-7163.MCT-18-1399
Reviews | AuthorChoice

ATM Dysfunction in Pancreatic Adenocarcinoma and Associated Therapeutic Implications

Samantha A. Armstrong, Christopher W. Schultz, Ariana Azimi-Sadjadi, Jonathan R. Brody and Michael J. Pishvaian

Mol Cancer Ther November 1 2019 18 (11) 1899-1908; DOI:10.1158/1535-7163.MCT-19-0208
Reviews

Targeting the EGFR and Immune Pathways in Squamous Cell Carcinoma of the Head and Neck (SCCHN): Forging a New Alliance

Nabil F. Saba, Zhuo Gerogia Chen, Missak Haigentz, Paolo Bossi, Alessandra Rinaldo, Juan P. Rodrigo, Antti A. Mäkitie, Robert P. Takes, Primoz Strojan, Jan B. Vermorken and Alfio Ferlito

Mol Cancer Ther November 1 2019 18 (11) 1909-1915; DOI:10.1158/1535-7163.MCT-19-0214

Main menu

User menu

Search

From the Current Issue

Recent Reviews

OnlineFirst Articles

Articles

Info for

About MCT